


## Dokumentasjonsark: Nasjonal faglig retningslinje for hjerneslag

Spørsmål 2.8: Er ASA som monoterapi like effektiv som ASA/dipyridamol eller clopidogrel alene?

<b>P</b>	Pasienter med hjerneinfarkt eller TIA uten indikasjon for antikoagulasjon	
<b>I</b>	Antiplatebehandling	Dato for søk: 23.09.2016
<b>C</b>	ASA/dipyridamol eller clopidogrel versus ASA alene	Søk oppdatert dato:
<b>O</b>	Recidiv hjerneinfarkt, død, blødningskomplikasjoner	Bibliotek for helseforvaltningen



\* Se tabell 2 for årsak til eksklusjon av studier etter vurdering av fulltekst

**Tabell 1a. Inkluderte systematiske oversikter (oversiktsartikler).**

Forfatter, år	Tittel	Metodisk kvalitet	Siste litteratursøk
Li, Zhou, Zhou, & Zhou, 2013	The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.	Moderat	August 2012
Niu, Guo, Jin, Xing, & Yang, 2016	Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis	Høy	Mars 2015

**Tabell 2. Ekskluderte referanser. Sammendraget/tittel funnet relevant, ekskludert etter vurdering av fulltekst av artikkel.**

Forfatter, år	Kommentar/begrunnelse for eksklusjon
Anonymous, 1994	Lav overførbarhet til PICO; utgår til fordel for mer oppdatert kunnskap
Aronow, 1999	Ikke en systematisk litteraturoversikt
Aronow, 2014	Ikke en systematisk litteraturoversikt (kommentar-artikkel)
Asdaghi & Romano, 2015	Ikke en systematisk litteraturoversikt
Chaturvedi, 2008	Ikke en systematisk litteraturoversikt
De Schryver, Algra, & van Gijn, 2003	Møter ikke PICO grunnet studiepopulasjon
De Schryver, Algra, & van Gijn, 2006	Møter ikke PICO grunnet studiepopulasjon
De Schryver, Algra, & van Gijn, 2007	Møter ikke PICO grunnet studiepopulasjon
Diener, 2006	Ikke en systematisk litteraturoversikt
Diener, Weimar, & Weber, 2010	Ikke en systematisk litteraturoversikt
Ge et al., 2016	Møter ikke PICO grunnet intervensjon og kontrollbehandling
Geeganage et al., 2012	Utgår til fordel for mer oppdatert kunnskap
Gouya et al., 2014	Møter ikke PICO grunnet studiepopulasjon og intervensjon
Greenhalgh et al., 2011	Utgår til fordel for mer oppdatert kunnskap
Greving et al., 2015	Protokoll

Halkes et al., 2008	Utgår til fordel for mer oppdatert kunnskap
Hankey, 2007	Ikke en systematisk litteraturoversikt
Huang et al., 2013	Møter ikke PICO grunnet kontrollbehandling
Lee et al., 2013	Møter ikke PICO grunnet kontrollbehandling
Malloy, Kanaan, Silva, & Donovan, 2013	Utgår til fordel for mer oppdatert kunnskap
McGrath et al., 2011	Møter ikke PICO grunnet intervensjon og kontrollbehandling
Rothwell et al., 2016	Ikke en systematisk litteraturoversikt
L. Tan et al., 2015	Møter ikke PICO grunnet intervensjonsbehandling
S. Tan et al., 2015	Møter ikke PICO grunnet intervensjonsbehandling
Thijs, Lemmens, & Fieuws, 2008	Utgår til fordel for mer oppdatert kunnskap
Verro, Gorelick, & Nguyen, 2008	Utgår til fordel for mer oppdatert kunnskap
Wang et al., 2016	Oppgir kun direkte estimat (nettverksanalyse) for ett av arbeidsgruppens ønskede utfall. Utgår til fordel for annen kunnskap som har bedre overførbarhet til PICO
Wong et al., 2013	Oppgir kun estimat for ett av arbeidsgruppens ønskede utfall. Utgår til fordel for annen kunnskap som har bedre overførbarhet til PICO
Xie, Zheng, Zhong, & Song, 2015	Møter PICO, men utgår grunnet lav tillit til forfatterne innhenting av data (hendelser) fra de inkluderte studiene
Zhang et al., 2015	Møter ikke PICO grunnet intervensjonsbehandling

---

**Fullstendig referanseliste (inkluderte og ekskluderte referanser).**

- Anonymous. (1994). Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.[Erratum appears in *BMJ* 1994 Jun 11;308(6943):1540]. *BMJ*, 308(6921), 81-106.
- Aronow, W. S. (1999). Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. *Drugs and Aging*, 15(2), 91-101.
- Aronow, W. S. (2014). Systematic review and meta-analysis: Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy

- approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack. *Evidence-Based Medicine*, 19(3), 94.
- Asdaghi, N., & Romano, J. G. (2015). Dual Antiplatelet Therapy in Acute Ischemic Stroke. *Current Atherosclerosis Reports*, 17 (7) (no pagination)(37).
- Chaturvedi, S. (2008). Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. *Clinical Therapeutics*, 30(7), 1196-1205.
- De Schryver, E. L., Algra, A., & van Gijn, J. (2003). Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. *Cochrane Database of Systematic Reviews*(1), CD001820.
- De Schryver, E. L., Algra, A., & van Gijn, J. (2006). Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. *Cochrane Database of Systematic Reviews*(2), CD001820.
- De Schryver, E. L., Algra, A., & van Gijn, J. (2007). Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. *Cochrane Database of Systematic Reviews*(3), CD001820.
- Diener, H. C. (2006). Primary and secondary stroke prevention with antiplatelet drugs. *Current Pharmaceutical Design*, 12(10), 1293-1297.
- Diener, H. C., Weimar, C., & Weber, R. (2010). Antiplatelet therapy in secondary stroke prevention--state of the art. *Journal of Cellular and Molecular Medicine*, 14(11), 2552-2560. doi:<http://dx.doi.org/10.1111/j.1582-4934.2010.01163.x>
- Ge, F., Lin, H., Liu, Y., Li, M., Guo, R., Ruan, Z., & Chang, T. (2016). Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. *European Journal of Neurology*, 23(6), 1051-1057. doi:<http://dx.doi.org/10.1111/ene.12982>
- Geeganage, C. M., Diener, H. C., Algra, A., Chen, C., Topol, E. J., Dengler, R., . . . Acute Antiplatelet Stroke Trialists, C. (2012). Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. *Stroke*, 43(4), 1058-1066. doi:<http://dx.doi.org/10.1161/STROKEAHA.111.637686>
- Gouya, G., Arrich, J., Wolzt, M., Huber, K., Verheugt, F. W., Gurbel, P. A., . . . Siller-Matula, J. M. (2014). Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. *Stroke*, 45(2), 492-503. doi:<http://dx.doi.org/10.1161/STROKEAHA.113.002590>
- Greenhalgh, J., Bagust, A., Boland, A., Martin Saborido, C., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. *Health technology assessment (Winchester, England)*, 15(31), 1-178. doi:<http://dx.doi.org/10.3310/hta15310>
- Greving, J. P., Diener, H. C., Csiba, L., Hacke, W., Kappelle, L. J., Koudstaal, P. J., . . . Cerebrovascular Antiplatelet Trialists' Collaborative, G. (2015). Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design. *International Journal of Stroke*, 10 Suppl A100, 145-150. doi:<http://dx.doi.org/10.1111/ijs.12581>
- Halkes, P. H., Gray, L. J., Bath, P. M., Diener, H. C., Guiraud-Chaumeil, B., Yatsu, F. M., & Algra, A. (2008). Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. *Journal of Neurology, Neurosurgery and Psychiatry*, 79(11), 1218-1223. doi:<http://dx.doi.org/10.1136/jnnp.2008.143875>
- Hankey, G. J. (2007). Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. *Current Medical Research and Opinion*, 23(6), 1453-1462.
- Huang, Y., Li, M., Li, J. Y., Li, M., Xia, Y. P., Mao, L., & Hu, B. (2013). The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a

- systematic review. *PLoS ONE [Electronic Resource]*, 8(6), e65754.  
doi:<http://dx.doi.org/10.1371/journal.pone.0065754>
- Lee, M., Saver, J. L., Hong, K. S., Rao, N. M., Wu, Y. L., & Ovbiagele, B. (2013). Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. *Annals of Internal Medicine*, 159(7), 463-470.  
doi:<http://dx.doi.org/10.7326/0003-4819-159-7-201310010-00006>
- Li, X., Zhou, G., Zhou, X., & Zhou, S. (2013). The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. *Journal of the Neurological Sciences*, 332(1-2), 92-96.  
doi:<http://dx.doi.org/10.1016/j.jns.2013.06.025>
- Malloy, R. J., Kanaan, A. O., Silva, M. A., & Donovan, J. L. (2013). Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. *Clinical Therapeutics*, 35(10), 1490-1500.
- McGrath, E., O'Conghaile, A., Eikelboom, J. W., Dinneen, S. F., Oczkowski, C., & O'Donnell, M. J. (2011). Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. *Cerebrovascular Diseases*, 32(1), 22-27. doi:<http://dx.doi.org/10.1159/000324629>
- Niu, P. P., Guo, Z. N., Jin, H., Xing, Y. Q., & Yang, Y. (2016). Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. *BMJ Open*, 6(3), e009013. doi:<http://dx.doi.org/10.1136/bmjopen-2015-009013>
- Rothwell, P. M., Algra, A., Chen, Z., Diener, H. C., Norrving, B., & Mehta, Z. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. *Lancet*, 388(10042), 365-375.  
doi:[http://dx.doi.org/10.1016/S0140-6736\(16\)30468-8](http://dx.doi.org/10.1016/S0140-6736(16)30468-8)
- Tan, L., Margaret, B., Zhang, J. H., Hu, R., Yin, Y., Cao, L., . . . Zhang, Y. (2015). Efficacy and safety of cilostazol therapy in ischemic stroke: A meta-analysis. *Journal of Stroke and Cerebrovascular Diseases*, 24(5), 930-938.
- Tan, S., Xiao, X., Ma, H., Zhang, Z., Chen, J., Ding, L., . . . Hong, H. (2015). Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. *PLoS ONE [Electronic Resource]*, 10(8), e0135372. doi:<http://dx.doi.org/10.1371/journal.pone.0135372>
- Thijs, V., Lemmens, R., & Fieuws, S. (2008). Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. *European Heart Journal*, 29(9), 1086-1092. doi:<http://dx.doi.org/10.1093/eurheartj/ehn106>
- Verro, P., Gorelick, P. B., & Nguyen, D. (2008). Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. *Stroke*, 39(4), 1358-1363.  
doi:<http://dx.doi.org/10.1161/STROKEAHA.107.496281>
- Wang, W., Zhang, L., Liu, W., Zhu, Q., Lan, Q., & Zhao, J. (2016). Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis. *Journal of Stroke and Cerebrovascular Diseases*, 25(5), 1081-1089.
- Wong, K. S. L., Wang, Y., Leng, X., Mao, C., Tang, J., Bath, P. M. W., . . . Lin, W. (2013). Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: An updated systematic review and meta-analysis. *Circulation*, 128(15), 1656-1666.
- Xie, W., Zheng, F., Zhong, B., & Song, X. (2015). Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis. *Journal of the American Heart Association*, 4(8), e002259. doi:<http://dx.doi.org/10.1161/JAHA.115.002259>
- Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., . . . Yan, C. (2015). Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. *Cerebrovascular Diseases*, 39(1), 13-22.  
doi:<http://dx.doi.org/10.1159/000369778>